Overcoming Sorafenib Treatment-Resistance in Hepatocellular Carcinoma: A Future Perspective at a Time of Rapidly Changing Treatment Paradigms.
Jiang Chen,Dan G Duda
DOI: https://doi.org/10.1016/j.ebiom.2020.102644
IF: 11.205
2020-01-01
EBioMedicine
Abstract:Hepatocellular carcinoma (HCC) has become the second leading cause of cancer-related death in the world due to a steady increase in the incidence rate, typical liver damage, and limited efficacy offered by the existing therapies for advanced stages of the disease. Systemic therapy with tyrosine kinase inhibitors is now recommended by most guidelines for patients not eligible for locoregional therapies, including those who have undergone surgical resection, liver transplantation or tumor ablation. However, the efficacy of systemic therapy remains limited despite the significant developments made in this area [[1]Kudo M. Targeted and immune therapies for hepatocellular carcinoma: predictions for 2019 and beyond.World J Gastroenterol. 2019; 25: 789-807Crossref PubMed Scopus (98) Google Scholar]. Sorafenib was consistently shown to be beneficial for patients with advanced HCC in multiple phase III trials conducted since 2007 [[2]Llovet J.M. Montal R. Sia D. Finn R.S. Molecular therapies and precision medicine for hepatocellular carcinoma.Nat Rev Clin Oncol. 2018; 15: 599-616Crossref PubMed Scopus (899) Google Scholar]. Sorafenib is a multi-kinase inhibitor that is considered as an anti-angiogenic drug because of its inhibitory effect on the vascular endothelial growth factor (VEGF) receptor (VEGFR) pathways. However, sorafenib has been shown to elicit numerous off-target effects in other cellular regulatory pathways including RAF1, PDGFRs, KIT as well as on other kinases [[3]Wilhelm S. Carter C. Lynch M. Lowinger T. Dumas J. Smith R.A. et al.Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.Nat Rev Drug Discov. 2006; 5: 835-844Crossref PubMed Scopus (1399) Google Scholar]. Thus, sorafenib treatment is expected to have pleiotropic effects on HCC and other cell types within the tumor microenvironment (TME) including but not limited to infiltrating stellate cells and immune cells [[3]Wilhelm S. Carter C. Lynch M. Lowinger T. Dumas J. Smith R.A. et al.Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.Nat Rev Drug Discov. 2006; 5: 835-844Crossref PubMed Scopus (1399) Google Scholar]. Understanding these complex effects is critical, as the exact mechanisms of benefit remain unclear, treatment responses are rare and transient, and the occurrence of resistance is common – with overall increases in survival of only 3 months. Since 2017, the treatment options for advanced HCC have expanded beyond sorafenib. Based on successful randomized phase III trials, two other multitargeted tyrosine kinase inhibitors (regorafenib and cabozantinib) are now approved as a second-line treatment for patients with sorafenib-resistant HCC [[2]Llovet J.M. Montal R. Sia D. Finn R.S. Molecular therapies and precision medicine for hepatocellular carcinoma.Nat Rev Clin Oncol. 2018; 15: 599-616Crossref PubMed Scopus (899) Google Scholar]. Similarly, an anti-VEGFR2 antibody (ramucirumab) was approved in this setting for patients with high levels (>400 ng/ml) of alphafetoprotein [[2]Llovet J.M. Montal R. Sia D. Finn R.S. Molecular therapies and precision medicine for hepatocellular carcinoma.Nat Rev Clin Oncol. 2018; 15: 599-616Crossref PubMed Scopus (899) Google Scholar]. These approaches have demonstrated an increased median overall survival between 1 and 3 months but, as with sorafenib, they failed to show durable therapeutic responses. Preliminary data from the use of immune checkpoint blockers (ICBs) has shown some encouraging durable responses in approximately 15% of the patients, even in those who received prior sorafenib treatment [[2]Llovet J.M. Montal R. Sia D. Finn R.S. Molecular therapies and precision medicine for hepatocellular carcinoma.Nat Rev Clin Oncol. 2018; 15: 599-616Crossref PubMed Scopus (899) Google Scholar]. However, two recently completed randomized phase III trials of ICBs have failed to reach the prespecified trial endpoints of increased progression-free and overall survival in patients who progressed while undergoing treatment with sorafenib. Thus, defining the underlying mechanisms of sorafenib resistance is still of great significance. In this issue of EBioMedicine, Xia et al. provide an overview of how the TME and tumor metabolism may mediate sorafenib resistance [[4]Xia S. Pan Y. Liang Y. Xu J. Cai X. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma.EBioMedicine. 2020; 51102610Summary Full Text Full Text PDF PubMed Scopus (90) Google Scholar]. Of particular significance, they discuss how the HCC microenvironment and metabolism might regulate cell stemness, mesenchymal state, and resistance to sorafenib via epigenetic mechanisms. The review provides a comprehensive and integrative perspective on the intricate mechanisms of acquired resistance reported for sorafenib using an epithelial-mesenchymal transition and cancer stem cell-based models. Since sorafenib is a multi-target agent that is widely used worldwide, understanding its resistance-associated mechanisms will have great significance not only for establishing clinical biomarkers of response, but may also serve to guide the development of new therapeutic targets. The review appropriately discusses the available evidence regarding sorafenib resistance-associated mechanisms and highlights new avenues in identification of suitable targets that may provide a synergistic effect with sorafenib. As discussed in the review, an important research question is the role of the specific TME of HCC. The vast majority of HCCs occur with underlying hepatic damage (characterized by pathological liver vascular, inflammatory and pro-fibrotic responses); and highly abnormal TME, also characterized by abnormal angiogenesis, immunosuppression, and fibrosis [[5]Hernandez-Gea V. Toffanin S. Friedman S.L. Llovet J.M. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.Gastroenterology. 2013; 144: 512-527Summary Full Text Full Text PDF PubMed Scopus (516) Google Scholar]. It is currently unclear whether sorafenib can overcome these abnormalities in the damaged liver and the TME of HCC. In our research, we found pronounced anti-vascular effects and increased hypoxia, inflammatory/myeloid cell infiltration and fibrosis in the TME of HCC—mediated by stromal-derived factor (SDF)-1α/CXCR4 pathway—after sorafenib treatment in murine models [[6]Chen Y. Huang Y. Reiberger T. Duyverman A.M. Huang P. Samuel R. et al.Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.Hepatology. 2014; 59: 1435-1447Crossref PubMed Scopus (151) Google Scholar]. Preventing these treatment-induced effects using a CXCR4 inhibitor was effective in enhancing sorafenib treatment response and in reprogramming of the TME to enhance responses to sorafenib when combined with ICB [[6]Chen Y. Huang Y. Reiberger T. Duyverman A.M. Huang P. Samuel R. et al.Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.Hepatology. 2014; 59: 1435-1447Crossref PubMed Scopus (151) Google Scholar,[7]Fukumura D. Kloepper J. Amoozgar Z. Duda D.G. Jain R.K. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Nat Rev Clin Oncol. 2018; 15: 325-340Crossref PubMed Scopus (835) Google Scholar]. It has been reported that sorafenib-induced hypoxia promotes the activation of hypoxia-inducible factor (HIF)-1α and HCC cell resistance to sorafenib [[8]Liang Y. Zheng T. Song R. Wang J. Yin D. Wang L. et al.Hypoxia-mediated sorafenib resistance can be overcome by EF24 through von Hippel–Lindau tumor suppressor-dependent HIF-1alpha inhibition in hepatocellular carcinoma.Hepatology. 2013; 57: 1847-1857Crossref PubMed Scopus (201) Google Scholar]. Moreover, analysis of clinical and pathology data showed that tumor-associated neutrophils recruit macrophages and T-regulatory cells in promoting resistance to sorafenib [[9]Zhou S.L. Zhou Z.J. Hu Z.Q. Huang X.W. Wang Z. Chen E.B. et al.Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib.Gastroenterology. 2016; 150 (e17): 1646-1658Summary Full Text Full Text PDF PubMed Scopus (425) Google Scholar]. Besides, tumor metabolism has been implicated in sorafenib resistance, as key enzymes in glycolysis were found to be overexpressed in patients with sorafenib resistant HCC [[10]Wong T.L. Ng K.Y. Tan K.V. Chan L.H. Zhou L. Che N. et al.CRAF methylation by PRMT6 regulates aerobic glycolysis driven hepatocarcinogenesis via ERK-dependent PKM2 nuclear relocalization and activation.Hepatology. 2019; (ePub on Aug 30, 2019)https://doi.org/10.1002/hep.30923Crossref Scopus (46) Google Scholar]. Overall, these results suggest that inhibiting glycolysis by targeting these key enzymes may be an effective strategy to target treatment resistance, especially under sorafenib-induced hypoxic conditions. They also raise other unanswered questions to elucidate the role of the TME as a target for therapy, in a time of rapidly changing treatment paradigms. Lenvatinib has shown equivalent efficacy with sorafenib and is increasingly being used as the first-line treatment option [[1]Kudo M. Targeted and immune therapies for hepatocellular carcinoma: predictions for 2019 and beyond.World J Gastroenterol. 2019; 25: 789-807Crossref PubMed Scopus (98) Google Scholar]. Moreover, a combination of an anti-VEGF antibody with ICB has shown superiority to sorafenib in a phase III trial (IMbrave150 study). These developments have impacted sorafenib's use and the trend is likely to continue. The mechanisms of resistance to sorafenib in such a setting (post-lenvatinib or ICB treatment) are unknown, but future strategies might involve vascular normalization rather than treatments that increase tumor hypoxia [[7]Fukumura D. Kloepper J. Amoozgar Z. Duda D.G. Jain R.K. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Nat Rev Clin Oncol. 2018; 15: 325-340Crossref PubMed Scopus (835) Google Scholar]. The exact role of sorafenib and tumor metabolism in these rapidly evolving treatment strategies remains to be established. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinomaIn most cases, sorafenib-resistant HCC cells exhibit significant mesenchymal phenotype and stemness features. In this context, tumor cells might undergo cell fate transition in response to sorafenib or other targeted drugs in the presence or absence of genetic mutations. Therefore, understanding the major characteristics of drug-resistant cells state helps to discover new treatments that overcome drug resistance. To note, little is known about the metabolic or microenvironmental aspects of the certain tumor cell states beyond the genome. Full-Text PDF Open Access